Andrew Pollack has covered the business and science of biotechnology for the New York Times since the 1980’s. He began focusing exclusively on that subject in 2000, during the frenzy over the sequencing of the human genome. Over the next 16 years until his retirement two years ago, he wrote about drug development and pricing, diagnostics, bio-entrepreneurs, public health, genomics, DNA engineering and editing, and genetically modified crops. In all, Andy spent 35 years at the Times, initially covering all things electronic, including the introductions of the IBM PC and the Macintosh and the breakup of the Bell telephone system. In 1985 he became the first Times reporter assigned to the San Francisco bureau to cover Silicon Valley. He was also a correspondent in Tokyo for five years. Born and raised in Queens, New York, Andy holds a bachelor’s and a master’s degree in civil and environmental engineering, from Princeton and MIT, respectively.